Coming to you from Congress, it's the event you've been waiting for. Bright and early on Thursday morning, attendees at the 48th annual conference made their way to the doors of the Henry B. Gonzalez Convention Center in San Antonio, TX, for the opening ceremony and keynote address. Watch as oncology nurses from near and far arrive on our red carpet.

Macy is a 57-year-old patient with a history of hormone receptor–positive invasive ductal carcinoma of the right breast, diagnosed in 2017. She achieved complete remission after chemotherapy with anthracycline plus paclitaxel followed by bilateral mastectomy with reconstruction in 2018.

Coming to you from Congress, join us as we speak with Oncology Nursing Foundation President Laura Benson about what attendees can expect at the 48th Annual ONS Congress and how oncology nurses everywhere can support the profession.

For nearly 2,500 years, nonmaleficence, or “do no harm,” has been a fundamental tenet of medical ethics. Yet none of today’s U.S. breast, cervical, colorectal, lung, or prostate cancer screening guidelines report all of the harms associated with screening tests, researchers said in study results published in Annals of Internal Medicine.

Under the U.S. Food and Drug Administration’s (FDA’s) fast-track approval process, nadofaragene firadenovec-vncg (Adstiladrin®) became the first gene therapy approved for the treatment of high-risk non-muscle invasive bladder cancer. Approximately 75% of newly diagnosed bladder cancers are classified as non-muscle invasive. Bacillus Calmette Guérin has been used as first-line therapy for more than 20 years, but eventually 30%–50% of patients stop responding, and nadofaragene firadenovec-vncg offers a new treatment option.

On April 19, 2023, the U.S. Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy®) with rituximab, cyclophosphamide, doxorubicin, and prednisone for adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified, or high-grade B-cell lymphoma and who have an International Prognostic Index score of 2 or greater.

Across disciplines, all healthcare providers take a practice oath that supports the principle of nonmaleficence (“first, do no harm”)—and so does the Centers for Medicare and Medicaid Services (CMS), several agency leaders wrote in a March 2023 blog post. The authors called for increased awareness of patient safety and highlighted ways CMS is taking action.

Joe Camel, the Marlboro Man, and the women who’ve “come a long way, baby” with Virginia Slims are marketing mascots that created an image of smoking as cool, chic, and classy—a concept that’s still cemented in the minds of many Americans today. For the past 30 years, public awareness campaigns have battled that belief among young people to dramatically curtail underage smoking, finally reaching a real reduction in youth tobacco use.

On April 17, 2023, the U.S. Food and Drug Administration approved omidubicel-onlv (Omisirge^®) for use in adult and pediatric patients aged 12 years and older with hematologic malignancies receiving umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.